{"count": 175, "results": [{"_id": "39405564", "pmid": 39405564, "title": "Investigating the Transfer of Lisinopril into Human Milk: A Quantitative Analysis.", "journal": "J Cardiovasc Pharmacol", "authors": ["Chugh J", "Dai J", "Datta P", "Krutsch K"], "date": "2024-10-15T00:00:00Z", "doi": "10.1097/FJC.0000000000001642", "meta_date_publication": "2024 Oct 15", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50265.285, "text_hl": "...@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@ is commonly prescribed to manage conditions such as @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@heart failure@@@. ", "citations": {"NLM": "Chugh J, Dai J, Datta P, Krutsch K. Investigating the Transfer of Lisinopril into Human Milk: A Quantitative Analysis. J Cardiovasc Pharmacol. 2024 Oct 15;():. PMID: 39405564", "BibTeX": "@article{39405564, title={Investigating the Transfer of Lisinopril into Human Milk: A Quantitative Analysis.}, author={Chugh J and Dai J and Datta P and Krutsch K}, journal={J Cardiovasc Pharmacol}}"}}, {"_id": "37304386", "pmid": 37304386, "pmcid": "PMC10250023", "title": "A Fatal Case of Lisinopril-Induced Acute Necrotizing Pancreatitis", "journal": "Cureus", "authors": ["Masarweh OM", "Al-Moussally F", "Meruvia Garron JP", "Kunadia A", "Karasik O", "Asmar A"], "date": "2023-06-07T00:00:00Z", "doi": "10.7759/cureus.40071", "meta_date_publication": "2023 Jun", "meta_volume": "15", "meta_issue": "6", "meta_pages": "e40071", "score": 50263.953, "text_hl": "Angiotensin-converting enzyme inhibitors (ACE-I), such as @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, are used as first-line therapy in the treatment of @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@, @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@heart failure@@@ with reduced ejection fraction, and @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@proteinuric chronic kidney disease@@@ due to their beneficial effects on reducing morbidity and mortality. ", "citations": {"NLM": "Masarweh OM, Al-Moussally F, Meruvia Garron JP, Kunadia A, Karasik O, Asmar A. A Fatal Case of Lisinopril-Induced Acute Necrotizing Pancreatitis Cureus. 2023 Jun;15(6):e40071. PMID: 37304386", "BibTeX": "@article{37304386, title={A Fatal Case of Lisinopril-Induced Acute Necrotizing Pancreatitis}, author={Masarweh OM and Al-Moussally F and Meruvia Garron JP and Kunadia A and Karasik O and Asmar A}, journal={Cureus}, volume={15}, number={6}, pages={e40071}}"}}, {"_id": "39350862", "pmid": 39350862, "title": "An Unusual Complication of Lisinopril: A Report of Iatrogenic Henoch-Schonlein Purpura.", "journal": "Cureus", "authors": ["Santos S", "Santos F", "Fróis Cunha I", "Rato M", "Camões S"], "date": "2024-08-31T00:00:00Z", "doi": "10.7759/cureus.68323", "meta_date_publication": "2024 Aug", "meta_volume": "16", "meta_issue": "8", "meta_pages": "e68323", "score": 50261.234, "text_hl": "After excluding @DISEASE_Communicable_Diseases @DISEASE_MESH:D003141 @@@infectious@@@, @DISEASE_Autoimmune_Diseases @DISEASE_MESH:D001327 @@@autoimmune@@@, and @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@neoplastic@@@ pathologies, the possibility of @DISEASE_IgA_Vasculitis @DISEASE_MESH:D011695 @@@HSP@@@ associated with taking @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@, which had been recently initiated after hospitalization for acute @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@heart failure@@@, was assumed. ", "citations": {"NLM": "Santos S, Santos F, Fróis Cunha I, Rato M, Camões S. An Unusual Complication of Lisinopril: A Report of Iatrogenic Henoch-Schonlein Purpura. Cureus. 2024 Aug;16(8):e68323. PMID: 39350862", "BibTeX": "@article{39350862, title={An Unusual Complication of Lisinopril: A Report of Iatrogenic Henoch-Schonlein Purpura.}, author={Santos S and Santos F and Fróis Cunha I and Rato M and Camões S}, journal={Cureus}, volume={16}, number={8}, pages={e68323}}"}}, {"_id": "33189627", "pmid": 33189627, "title": "Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.", "journal": "JACC Heart Fail", "authors": ["Khayyat-Kholghi M", "Oparil S", "Davis BR", "Tereshchenko LG"], "date": "2021-02-01T00:00:00Z", "doi": "10.1016/j.jchf.2020.09.006", "meta_date_publication": "2021 Feb", "meta_volume": "9", "meta_issue": "2", "meta_pages": "100-111", "score": 50259.95, "text_hl": "In fully adjusted causal mediation analysis, the relative change in eGFR mediated 18% of the effect of @CHEMICAL_Chlorthalidone @CHEMICAL_MESH:D002752 @@@chlorthalidone@@@, and 33% of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ on incident symptomatic @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@HF@@@, and 25% of the effect of @CHEMICAL_Chlorthalidone @CHEMICAL_MESH:D002752 @@@chlorthalidone@@@, and 41% of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ on hospitalized/fatal @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@HF@@@. ", "citations": {"NLM": "Khayyat-Kholghi M, Oparil S, Davis BR, Tereshchenko LG. Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study. JACC Heart Fail. 2021 Feb;9(2):100-111. PMID: 33189627", "BibTeX": "@article{33189627, title={Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.}, author={Khayyat-Kholghi M and Oparil S and Davis BR and Tereshchenko LG}, journal={JACC Heart Fail}, volume={9}, number={2}, pages={100-111}}"}}, {"_id": "33048477", "pmid": 33048477, "pmcid": "PMC7993260", "title": "Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers", "journal": "Clin Transl Sci", "authors": ["Misaka S", "Ono Y", "Uchida A", "Ono T", "Abe O", "Ogata H", "Sato H", "Suzuki M", "Onoue S", "Shikama Y", "Shimomura K"], "date": "2021-03-01T00:00:00Z", "doi": "10.1111/cts.12905", "meta_date_publication": "2021 Mar", "meta_volume": "14", "meta_issue": "2", "meta_pages": "476-480", "score": 50257.2, "text_hl": "...@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@, a highly hydrophilic long-acting angiotensin-converting enzyme inhibitor, is frequently prescribed for the treatment of @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ and @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@congestive heart failure@@@. ", "citations": {"NLM": "Misaka S, Ono Y, Uchida A, Ono T, Abe O, Ogata H, Sato H, Suzuki M, Onoue S, Shikama Y, Shimomura K. Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers Clin Transl Sci. 2021 Mar;14(2):476-480. PMID: 33048477", "BibTeX": "@article{33048477, title={Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers}, author={Misaka S and Ono Y and Uchida A and Ono T and Abe O and Ogata H and Sato H and Suzuki M and Onoue S and Shikama Y and Shimomura K}, journal={Clin Transl Sci}, volume={14}, number={2}, pages={476-480}}"}}, {"_id": "39243877", "pmid": 39243877, "title": "Prevention of Heart Failure in Hypertension - the Role of Coronary Heart Disease Events Treated with Versus without Revascularization: the ALLHAT Study.", "journal": "Am J Cardiol", "authors": ["Chen V", "Davis BR", "Kapadia SR", "Kattan MW", "Tereshchenko LG"], "date": "2024-09-05T00:00:00Z", "doi": "10.1016/j.amjcard.2024.08.033", "meta_date_publication": "2024 Sep 5", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50252.664, "text_hl": "The proportion of reference interaction indicating direct harm due to CHD event for @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ (234% for @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@CHF@@@; 355% for @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@HHF@@@) and @CHEMICAL_Amlodipine @CHEMICAL_MESH:D017311 @@@amlodipine@@@ (244% for @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@CHF@@@; 468% for @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@HHF@@@) was greater than for @CHEMICAL_Chlorthalidone @CHEMICAL_MESH:D002752 @@@chlorthalidone@@@ (143% for @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@CHF@@@; 269% for @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@HHF@@@). ", "citations": {"NLM": "Chen V, Davis BR, Kapadia SR, Kattan MW, Tereshchenko LG. Prevention of Heart Failure in Hypertension - the Role of Coronary Heart Disease Events Treated with Versus without Revascularization: the ALLHAT Study. Am J Cardiol. 2024 Sep 5;():. PMID: 39243877", "BibTeX": "@article{39243877, title={Prevention of Heart Failure in Hypertension - the Role of Coronary Heart Disease Events Treated with Versus without Revascularization: the ALLHAT Study.}, author={Chen V and Davis BR and Kapadia SR and Kattan MW and Tereshchenko LG}, journal={Am J Cardiol}}"}}, {"_id": "36376029", "pmid": 36376029, "title": "Role of lisinopril in the therapeutic management of cardiovascular disease by targeting microtubule affinity regulating kinase 4: molecular docking and molecular dynamics simulation approaches.", "journal": "J Biomol Struct Dyn", "authors": ["Atiya A", "Alsayari A", "Bin Muhsinah A", "Almaghaslah D", "Bilgrami AL", "Abdulmonem WA", "Alorfi NM", "DasGupta D", "Ashraf GM", "Shamsi A", "Shahwan M"], "date": "2022-11-14T00:00:00Z", "doi": "10.1080/07391102.2022.2143425", "meta_date_publication": "2022 Nov 14", "meta_volume": "", "meta_issue": "", "meta_pages": "1-7", "score": 50252.2, "text_hl": "Additionally, MD simulation deciphered the structural dynamics and stability of the @GENE_MARK4 @GENE_57787 @@@MARK4@@@-@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ complex. The findings of MD studies established that minimal structural deviations are observed during simulation, affirming the stability of the @GENE_MARK4 @GENE_57787 @@@MARK4@@@-@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ complex. ", "citations": {"NLM": "Atiya A, Alsayari A, Bin Muhsinah A, Almaghaslah D, Bilgrami AL, Abdulmonem WA, Alorfi NM, DasGupta D, Ashraf GM, Shamsi A, Shahwan M. Role of lisinopril in the therapeutic management of cardiovascular disease by targeting microtubule affinity regulating kinase 4: molecular docking and molecular dynamics simulation approaches. J Biomol Struct Dyn. 2022 Nov 14;():1-7. PMID: 36376029", "BibTeX": "@article{36376029, title={Role of lisinopril in the therapeutic management of cardiovascular disease by targeting microtubule affinity regulating kinase 4: molecular docking and molecular dynamics simulation approaches.}, author={Atiya A and Alsayari A and Bin Muhsinah A and Almaghaslah D and Bilgrami AL and Abdulmonem WA and Alorfi NM and DasGupta D and Ashraf GM and Shamsi A and Shahwan M}, journal={J Biomol Struct Dyn}, pages={1-7}}"}}, {"_id": "33228503", "pmid": 33228503, "title": "[Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction].", "journal": "Kardiologiia", "authors": ["Babushkina GV", "Shaikhlislamova GI"], "date": "2020-10-10T00:00:00Z", "doi": "10.18087/cardio.2020.10.n1324", "meta_date_publication": "2020 Oct 10", "meta_volume": "60", "meta_issue": "10", "meta_pages": "33-37", "score": 50244.184, "text_hl": "[@CHEMICAL_Ivabradine @CHEMICAL_MESH:D000077550 @@@Ivabradine@@@ for Treatment of @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@Heart Failure@@@ with Preserved Ejection Fraction].", "citations": {"NLM": "Babushkina GV, Shaikhlislamova GI. [Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction]. Kardiologiia. 2020 Oct 10;60(10):33-37. PMID: 33228503", "BibTeX": "@article{33228503, title={[Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction].}, author={Babushkina GV and Shaikhlislamova GI}, journal={Kardiologiia}, volume={60}, number={10}, pages={33-37}}"}}, {"_id": "33140296", "pmid": 33140296, "title": "Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman.", "journal": "Int J Clin Pharm", "authors": ["Hanbali DA", "Hashmi KA", "Za'abi MA", "Al-Zakwani I"], "date": "2021-08-01T00:00:00Z", "doi": "10.1007/s11096-020-01190-2", "meta_date_publication": "2021 Aug", "meta_volume": "43", "meta_issue": "4", "meta_pages": "878-883", "score": 50243.824, "text_hl": "The use of angiotensin-converting-enzyme inhibitors (@CHEMICAL_Captopril @CHEMICAL_MESH:D002216 @@@captopril@@@, @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@) or angiotensin II receptor blockers (@CHEMICAL_Irbesartan @CHEMICAL_MESH:D000077405 @@@irbesartan@@@, @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@valsartan@@@), beta-blockers (@CHEMICAL_Bisoprolol @CHEMICAL_MESH:D017298 @@@bisoprolol@@@, @CHEMICAL_Carvedilol @CHEMICAL_MESH:D000077261 @@@carvedilol@@@) and @CHEMICAL_Spironolactone @CHEMICAL_MESH:D013148 @@@spironolactone@@@ along with their respective target doses were evaluated as per the European, American, and Canadian @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@heart failure@@@ guidelines. ", "citations": {"NLM": "Hanbali DA, Hashmi KA, Za'abi MA, Al-Zakwani I. Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman. Int J Clin Pharm. 2021 Aug;43(4):878-883. PMID: 33140296", "BibTeX": "@article{33140296, title={Evaluation of guideline-based cardiovascular medications and their respective doses in heart failure patients in Oman.}, author={Hanbali DA and Hashmi KA and Za'abi MA and Al-Zakwani I}, journal={Int J Clin Pharm}, volume={43}, number={4}, pages={878-883}}"}}, {"_id": "34214650", "pmid": 34214650, "pmcid": "PMC8570423", "title": "Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States", "journal": "J Card Fail", "authors": ["Vaduganathan M", "Li D", "Van Meijgaard J", "Warraich HJ"], "date": "2021-11-01T00:00:00Z", "doi": "10.1016/j.cardfail.2021.06.013", "meta_date_publication": "2021 Nov", "meta_volume": "27", "meta_issue": "11", "meta_pages": "1280-1284", "score": 50243.383, "text_hl": "We leveraged a large U.S. pharmacy-claims database to understand the use of evidence-based therapies in @<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@heart failure@@@ (@<m>DISEASE_Heart_Failure</m> @DISEASE_MESH:D006333 @@@HF@@@) care during the @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@coronavirus disease-2019@@@ (@DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@) pandemic.", "citations": {"NLM": "Vaduganathan M, Li D, Van Meijgaard J, Warraich HJ. Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States J Card Fail. 2021 Nov;27(11):1280-1284. PMID: 34214650", "BibTeX": "@article{34214650, title={Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States}, author={Vaduganathan M and Li D and Van Meijgaard J and Warraich HJ}, journal={J Card Fail}, volume={27}, number={11}, pages={1280-1284}}"}}]}